1. Sun JR, Kim SM, Seo MH, Kim MJ, Lee JH, Myoung H. Oral cancer incidence based on annual cancer statistics in Korea. J Korean Assoc Oral Maxillofac Surg. 2012; 38:20–28.
Article
2. Forman D, Bray F, Brewster DH, Gombe Mbalawa C, Kohler B, Piñeros M, et al. Cancer incidence in five continents Vol. X. Lyon: IARC Scientific Publication 164;2014. .
3. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999; 189:12–19. PMID:
10451482.
Article
4. van der Marel J, Berkhof J, Ordi J, Torné A, Del Pino M, van Baars R, et al. Attributing oncogenic human papillomavirus genotypes to high-grade cervical neoplasia: which type causes the lesion? Am J Surg Pathol. 2015; 39:496–504. PMID:
25353286.
5. Bosch FX, Lorincz A, Muñoz N, Meijer CJ, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol. 2002; 55:244–265. PMID:
11919208.
Article
6. Muñoz N, Bosch FX, de Sanjosé S, Herrero R, Castellsagué X, Shah KV, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003; 348:518–527. PMID:
12571259.
Article
7. de Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H. Classification of papillomaviruses. Virology. 2004; 324:17–27. PMID:
15183049.
Article
8. Buck CB, Cheng N, Thompson CD, Lowy DR, Steven AC, Schiller JT, et al. Arrangement of L2 within the papillomavirus capsid. J Virol. 2008; 82:5190–5197. PMID:
18367526.
Article
9. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer. 2002; 2:342–350. PMID:
12044010.
Article
10. Rautava J, Syrjänen S. Biology of human papillomavirus infections in head and neck carcinogenesis. Head Neck Pathol. 2012; 6(Suppl 1):S3–S15. PMID:
22782219.
Article
11. Lizano M, Berumen J, García-Carrancá A. HPV-related carcinogenesis: basic concepts, viral types and variants. Arch Med Res. 2009; 40:428–434. PMID:
19853182.
Article
12. Cardoso JC, Calonje E. Cutaneous manifestations of human papillomaviruses: a review. Acta Dermatovenerol Alp Pannonica Adriat. 2011; 20:145–154. PMID:
22131115.
13. Orth G. Host defenses against human papillomaviruses: lessons from epidermodysplasia verruciformis. Curr Top Microbiol Immunol. 2008; 321:59–83. PMID:
18727487.
Article
14. Lazarczyk M, Cassonnet P, Pons C, Jacob Y, Favre M. The EVER proteins as a natural barrier against papillomaviruses: a new insight into the pathogenesis of human papillomavirus infections. Microbiol Mol Biol Rev. 2009; 73:348–370. PMID:
19487731.
Article
15. Stoler MH. Human papillomaviruses and cervical neoplasia: a model for carcinogenesis. Int J Gynecol Pathol. 2000; 19:16–28. PMID:
10638450.
Article
16. Kreimer AR, Clifford GM, Boyle P, Franceschi S. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev. 2005; 14:467–475. PMID:
15734974.
Article
17. Miralles-Guri C, Bruni L, Cubilla AL, Castellsagué X, Bosch FX, de Sanjosé S. Human papillomavirus prevalence and type distribution in penile carcinoma. J Clin Pathol. 2009; 62:870–878. PMID:
19706632.
Article
18. Campisi G, Panzarella V, Giuliani M, Lajolo C, Di Fede O, Falaschini S, et al. Human papillomavirus: its identity and controversial role in oral oncogenesis, premalignant and malignant lesions (review). Int J Oncol. 2007; 30:813–823. PMID:
17332919.
19. Femiano F. Papilloma virus. Review of the literature. Note II. Diagnosis and treatment. Minerva Stomatol. 2000; 49:179–186. PMID:
11040544.
20. Miller CS, Johnstone BM. Human papillomavirus as a risk factor for oral squamous cell carcinoma: a meta-analysis, 1982-1997. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2001; 91:622–635. PMID:
11402272.
Article
21. Syrjänen K, Mäntyjärvi R, Saarikoski S, Väyrynen M, Syrjänen S, Parkkinen S, et al. Factors associated with progression of cervical human papillomavirus (HPV) infections into carcinoma in situ during a long-term prospective follow-up. Br J Obstet Gynaecol. 1988; 95:1096–1102. PMID:
2849985.
22. Pfister H. Human papillomaviruses and skin cancer. Semin Cancer Biol. 1992; 3:263–271. PMID:
1335790.
23. Münger K, Werness BA, Dyson N, Phelps WC, Harlow E, Howley PM. Complex formation of human papillomavirus E7 proteins with the retinoblastoma tumor suppressor gene product. EMBO J. 1989; 8:4099–4105. PMID:
2556261.
Article
24. Werness BA, Levine AJ, Howley PM. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science. 1990; 248:76–79. PMID:
2157286.
Article
25. Santoro V, Pozzuoli ML, Colella G. Role of human papilloma virus in precancerous and cancerous lesions of the oral cavity. Review of the literature. Minerva Stomatol. 1997; 46:595–601. PMID:
9489355.
26. Fornatora ML, Jones AC, Kerpel S, Freedman PD. It's time to modernize our approach to oral HPV lesions. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2001; 91:494–496. PMID:
11346722.
Article
27. Park MW, Cho YA, Kim SM, Myoung H, Lee JH, Lee SK. Focal epithelial hyperplasia arising after delivery of metal-ceramic fixed dental prosthesis. J Adv Prosthodont. 2014; 6:555–558. PMID:
25558348.
Article
28. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. IARC monographs on the evaluation of carcinogenic risks to humans: IARC monographs, volume 100B. A review of human carcinogens. B. Biological agents. Lyon: International Agency for Research on Cancer;2012. p. 278–280.
29. Fakhry C, Westra WH, Li S, Cmelak A, Ridge JA, Pinto H, et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst. 2008; 100:261–269. PMID:
18270337.
Article
30. Dayyani F, Etzel CJ, Liu M, Ho CH, Lippman SM, Tsao AS. Meta-analysis of the impact of human papillomavirus (HPV) on cancer risk and overall survival in head and neck squamous cell carcinomas (HNSCC). Head Neck Oncol. 2010; 2:15. PMID:
20587061.
Article
31. Bouda M, Gorgoulis VG, Kastrinakis NG, Giannoudis A, Tsoli E, Danassi-Afentaki D, et al. "High risk" HPV types are frequently detected in potentially malignant and malignant oral lesions, but not in normal oral mucosa. Mod Pathol. 2000; 13:644–653. PMID:
10874669.
Article
32. Kojima A, Maeda H, Sugita Y, Tanaka S, Kameyama Y. Human papillomavirus type 38 infection in oral squamous cell carcinomas. Oral Oncol. 2002; 38:591–596. PMID:
12167437.
Article
33. Kim KS, Park SA, Ko KN, Yi S, Cho YJ. Current status of human papillomavirus vaccines. Clin Exp Vaccine Res. 2014; 3:168–175. PMID:
25003090.
Article
34. Snow AN, Laudadio J. Human papillomavirus detection in head and neck squamous cell carcinomas. Adv Anat Pathol. 2010; 17:394–403. PMID:
20966645.
Article
35. Gillison ML, D'Souza G, Westra W, Sugar E, Xiao W, Begum S, et al. Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. J Natl Cancer Inst. 2008; 100:407–420. PMID:
18334711.
Article
36. Heck JE, Berthiller J, Vaccarella S, Winn DM, Smith EM, Shan'gina O, et al. Sexual behaviours and the risk of head and neck cancers: a pooled analysis in the International Head and Neck Cancer Epidemiology (INHANCE) consortium. Int J Epidemiol. 2010; 39:166–181. PMID:
20022926.
Article
37. Lajer CB, von Buchwald C. The role of human papillomavirus in head and neck cancer. APMIS. 2010; 118:510–519. PMID:
20553531.
Article
38. Mishra R. Biomarkers of oral premalignant epithelial lesions for clinical application. Oral Oncol. 2012; 48:578–584. PMID:
22342569.
Article
39. Napier SS, Speight PM. Natural history of potentially malignant oral lesions and conditions: an overview of the literature. J Oral Pathol Med. 2008; 37:1–10. PMID:
18154571.
Article
40. Villa A, Villa C, Abati S. Oral cancer and oral erythroplakia: an update and implication for clinicians. Aust Dent J. 2011; 56:253–256. PMID:
21884139.
Article
41. Greer RO Jr, Meyers A, Said SM, Shroyer KR. Is p16(INK4a) protein expression in oral ST lesions a reliable precancerous marker? Int J Oral Maxillofac Surg. 2008; 37:840–846. PMID:
18606525.
Article
42. Leemans CR, Braakhuis BJ, Brakenhoff RH. The molecular biology of head and neck cancer. Nat Rev Cancer. 2011; 11:9–22. PMID:
21160525.
Article
43. Feller L, Wood NH, Khammissa RA, Lemmer J. Human papillomavirus-mediated carcinogenesis and HPV-associated oral and oropharyngeal squamous cell carcinoma. Part 2: Human papillomavirus associated oral and oropharyngeal squamous cell carcinoma. Head Face Med. 2010; 6:15. PMID:
20633288.
Article
44. Markowitz LE, Tsu V, Deeks SL, Cubie H, Wang SA, Vicari AS, et al. Human papillomavirus vaccine introduction--the first five years. Vaccine. 2012; 30(Suppl 5):F139–F148. PMID:
23199957.
45. Castle PE, Maza M. Prophylactic HPV vaccination: past, present, and future. Epidemiol Infect. 2016; 144:449–468. PMID:
26429676.
Article
46. zur Hausen H, Gissmann L, Steiner W, Dippold W, Dreger I. Human papilloma viruses and cancer. Bibl Haematol. 1975; (43):569–571.
47. Zhou J, Sun XY, Stenzel DJ, Frazer IH. Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. Virology. 1991; 185:251–257. PMID:
1656586.
Article
48. Baker TS, Newcomb WW, Olson NH, Cowsert LM, Olson C, Brown JC. Structures of bovine and human papillomaviruses. Analysis by cryoelectron microscopy and three-dimensional image reconstruction. Biophys J. 1991; 60:1445–1456. PMID:
1663794.
Article
49. zur Hausen H. Papillomaviruses in the causation of human cancers: a brief historical account. Virology. 2009; 384:260–265. PMID:
19135222.
50. Kumaraswamy KL, Vidhya M. Human papilloma virus and oral infections: an update. J Cancer Res Ther. 2011; 7:120–127. PMID:
21768696.
Article
51. Syrjänen KJ, Pyrhönen S, Syrjänen SM, Lamberg MA. Immunohistochemical demonstration of human papilloma virus (HPV) antigens in oral squamous cell lesions. Br J Oral Surg. 1983; 21:147–153. PMID:
6307342.
Article
52. Cox MF, Scully C, Maitland N. Viruses in the aetiology of oral carcinoma? Examination of the evidence? Br J Oral Maxillofac Surg. 1991; 29:381–387. PMID:
1772858.
Article
53. Murray M. Progress in preventing cervical cancer: updated evidence on vaccination and screening [Internet]. Seattle (WA): Outlook 2010;27(2)/Program for Appropriate Technology in Health (PATH);cited 2016 Aug 27. Available from:
http://www.path.org/publications/files/RH_outlook_27_2.pdf.
55. Palefsky JM, Giuliano AR, Goldstone S, Moreira ED Jr, Aranda C, Jessen H, et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med. 2011; 365:1576–1585. PMID:
22029979.
Article
56. Huygen F, Verschueren K, McCabe C, Stegmann JU, Zima J, Mahaux O, et al. Investigating reports of complex regional pain syndrome: an analysis of HPV-16/18-adjuvanted vaccine post-licensure data. EBioMedicine. 2015; 2:1114–1121. PMID:
26501109.
Article
57. Garçon N, Chomez P, Van Mechelen M. GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives. Expert Rev Vaccines. 2007; 6:723–739. PMID:
17931153.
Article
58. Kash N, Lee MA, Kollipara R, Downing C, Guidry J, Tyring SK. Safety and efficacy data on vaccines and immunization to human papillomavirus. J Clin Med. 2015; 4:614–633. PMID:
26239350.
Article
60. Haupt RM, Sings HL. The efficacy and safety of the quadrivalent human papillomavirus 6/11/16/18 vaccine gardasil. J Adolesc Health. 2011; 49:467–475. PMID:
22018560.
Article
61. McNeil C. Who invented the VLP cervical cancer vaccines? J Natl Cancer Inst. 2006; 98:433. PMID:
16595773.
Article
62. Shi L, Sings HL, Bryan JT, Wang B, Wang Y, Mach H, et al. GARDASIL: prophylactic human papillomavirus vaccine development: from bench top to bed-side. Clin Pharmacol Ther. 2007; 81:259–264. PMID:
17259949.
63. Vichnin M, Bonanni P, Klein NP, Garland SM, Block SL, Kjaer SK, et al. An overview of quadrivalent human papillomavirus vaccine safety: 2006 to 2015. Pediatr Infect Dis J. 2015; 34:983–991. PMID:
26107345.
64. Slade BA, Leidel L, Vellozzi C, Woo EJ, Hua W, Sutherland A, et al. Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine. JAMA. 2009; 302:750–757. PMID:
19690307.
Article
65. Garland SM, Cheung TH, McNeill S, Petersen LK, Romaguera J, Vazquez-Narvaez J, et al. Safety and immunogenicity of a 9-valent HPV vaccine in females 12-26 years of age who previously received the quadrivalent HPV vaccine. Vaccine. 2015; 33:6855–6864. PMID:
26411885.
Article
66. Labadie J. Postlicensure safety evaluation of human papilloma virus vaccines. Int J Risk Saf Med. 2011; 23:103–112. PMID:
21673418.
Article
67. Brotherton JM, Ogilvie GS. Current status of human papillomavirus vaccination. Curr Opin Oncol. 2015; 27:399–404. PMID:
26258273.
Article
68. Brisson M, Laprise JF, Chesson HW, Drolet M, Malagón T, Boily MC, et al. Health and economic impact of switching from a 4-valent to a 9-valent HPV vaccination program in the United States. J Natl Cancer Inst. 2015; DOI:
10.1093/jnci/djv282.
Article
69. Bazan SB, de Alencar Muniz Chaves A, Aires KA, Cianciarullo AM, Garcea RL, Ho PL. Expression and characterization of HPV-16 L1 capsid protein in Pichia pastoris. Arch Virol. 2009; 154:1609–1617. PMID:
19756360.
Article
70. Rybicki EP, Williamson AL, Meyers A, Hitzeroth II. Vaccine farming in Cape Town. Hum Vaccin. 2011; 7:339–348. PMID:
21358269.
Article
71. Majewski S, Jablonska S. Immunology of HPV infection and HPV-associated tumors. Int J Dermatol. 1998; 37:81–95. PMID:
9542660.
72. Chang F. Role of papillomaviruses. J Clin Pathol. 1990; 43:269–276. PMID:
2160477.
Article
73. Tindle RW, Frazer IH. Immune response to human papillomaviruses and the prospects for human papillomavirus-specific immunisation. Curr Top Microbiol Immunol. 1994; 186:217–253. PMID:
8205843.
Article
74. Arya SC, Agarwal N. Extended coverage of HPV vaccination in middle-aged adults to prevent oropharyngeal cancers. Hum Vaccin Immunother. 2012; 8:959. PMID:
22777098.
Article
75. Ramqvist T, Dalianis T. An epidemic of oropharyngeal squamous cell carcinoma (OSCC) due to human papillomavirus (HPV) infection and aspects of treatment and prevention. Anticancer Res. 2011; 31:1515–1519. PMID:
21617204.
76. Matsushita K, Sasagawa T, Miyashita M, Ishizaki A, Morishita A, Hosaka N, et al. Oral and cervical human papillomavirus infection among female sex workers in Japan. Jpn J Infect Dis. 2011; 64:34–39. PMID:
21266753.
77. Zil-A-Rubab , Baig S, Siddiqui A, Nayeem A, Salman M, Qidwai MA, et al. Human papilloma virus--role in precancerous and cancerous oral lesions of tobacco chewers. J Pak Med Assoc. 2013; 63:1295–1298. PMID:
24392564.